An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder by Burghardt, Kyle J. et al.
432 VOLUME 8 • ISSUE 5 WWW.CTSJOURNAL.COM
 Background 
 Second generation antipsychotic (SGA) medications, 
commonly considered first-line therapy in schizophrenia 
medication management, have become an increasingly 
common pharmacotherapeutic choice in bipolar disorder. 1 
Despite proven effi  cacy, and their arguable superiority to fi rst 
generation antipsychotics in the treatment of schizophrenia, 
patient intolerance and discontinuation remain high. 2 Th is is 
likely due to a combination of factors including ineffi  cacy and 
side eff ects. A possible major concern and contributor to this 
nonadherence are the cardiometabolic side eff ects that include 
weight gain, insulin resistance, dyslipidemia, and the metabolic 
syndrome. Although the contribution of antipsychotics to the 
overall high rates of cardiovascular disease in schizophrenia 
and bipolar disorder is not fully know, their impact is likely 
significant based on the side effect profile of this class of 
medications. 3,4 
 Signifi cant amounts of research have been conducted to 
better understand the pathophysiological mechanisms and 
processes that underlie the therapeutic effi  cacy and side eff ects 
of SGAs within schizophrenia, and numerous pathways have been 
implicated in antipsychotic outcomes. 5,6 Currently there is little 
evidence to show that SGAs have diagnosis-specifi c mechanisms, 
however, some antipsychotic-induced side eff ects may occur at 
diff erent rates between bipolar and schizophrenia patients. 7,8 Also, 
these two populations may have diff erent tolerance levels for 
antipsychotics and antipsychotics are not always used to treat 
the same psychiatric symptoms in both populations. Despite a 
lack of evidence for antipsychotics exerting their eff ects through 
diagnosis-specific pathways, the lifestyle, diet and genetics 
of bipolar and schizophrenia patients may be unique. 9,10 It is 
currently not known if these factors create a diagnosis-specifi c 
“metabolomic environment” in which SGAs may aff ect their 
benefi cial or adverse outcomes. 
 Th e fi eld of pharmacometabolomics has emerged in the past 
10 years to assist in the understanding of drug eff ects in psychiatric 
illness. One of the fi rst reported pharmacometabolomic studies of 
antipsychotic use by Kaddurah-Daouk et al. utilized a lipidomic 
platform to investigate lipid changes aft er 2–3 weeks of olanzapine, 
risperidone, and aripiprazole treatment in schizophrenia. 11 Th eir 
work identifi ed several classes of lipids, including phospholipids, 
which were increased by treatment with all three drugs. In a 
follow-up study, McEvoy et al. conducted another lipidomic 
study to characterize the eff ects of 2 weeks of SGAs (risperidone 
or aripiprazole) on the plasma lipidome in fi rst episode and 
recurrent schizophrenia subjects. 12 Th eir fi ndings showed again, 
in fi rst episode patients, that antipsychotic treatment caused 
signifi cant changes in phospholipids and polyunsaturated fatty 
acids. Within the McEvoy study, recurrent schizophrenia patient’s 
phospholipids did not change, however there were changes in the 
polyunsaturated fatty acids of this patient subset. 
 Finally, work by Xuan et  al. using an untargeted serum 
metabolomics strategy to characterize the treatment eff ects of 
8-week risperidone monotherapy in schizophrenia found that 
myo-inositol, uric acid, tyrosine and tryptophan were most 
predictive as metabolite biomarkers in risperidone responders. 13 
 Signifi cant work has been conducted to look at the eff ects 
of antipsychotic treatment in the schizophrenia population 
however, to date, this has not been evaluated in the bipolar 
population and pharmacometabolomic profi les have not been 
compared between these two diagnostically distinct populations. 
Th is study aimed to take an unbiased metabolomics approach 
to investigate antipsychotic use in bipolar disorder. We utilized 
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 Abstract 
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a well-characterized set of bipolar and schizophrenia subjects 
on a narrowly defi ned set of psychopharmacology in order to 
describe the overall metabolite profi les of long-term antipsychotic 
use within bipolar disorder (SGA versus lithium) and across 
diagnoses (bipolar SGA versus schizophrenia SGA). 
 Methods 
 Subject population 
 Subjects were recruited from a cross-sectional parent study 
investigating the occurrence of antipsychotic-induced metabolic 
syndrome in the severely mentally ill. 14,15 Subjects were required 
to have a current diagnosis of bipolar I disorder or schizophrenia 
according to the Diagnostic and Statistics Manual for Mental 
Disorders, IV, Text Revision (DSM-IV-TR). 16 Diagnosis was 
confi rmed by the Structured Clinical Interview for DSM-IV-TR 
Diagnoses (SCID) performed by a trained research assistant and 
confi rmed via medical chart review. Subjects were included for 
metabolomic study if they (1) were stable on either a maintenance 
therapy of lithium or a second generation antipsychotic (SGA) 
for at least 6 months as determined by their primary physician 
or psychiatrist, (2) did not have metabolic abnormalities (e.g., 
diabetes, dyslipidemia, cardiovascular disease or obesity) prior to 
starting their SGA or lithium, and (3) were willing to participate. 
Potential subjects were excluded if they (1) were unable or 
unwilling to participate or (2) had an active substance abuse 
diagnosis (smoking was allowed). 
 Subjects meeting criteria were invited to participate at the 
Clinical Research Unit at the University of Michigan resulting 
in three groups for metabolomic study: (1) bipolar I subjects 
treated with SGA monotherapy, (2) bipolar I subjects treated 
with lithium monotherapy, and (3) schizophrenia subjects treated 
with SGA monotherapy. All study visits occurred within 2 hours 
of the subject’s normal waking time and in a fasting state (no 
food consumption for at least 10 hours prior to visit). Fasting 
blood samples were collected and serum was obtained within 20 
minutes, fl ash frozen and transferred to –80  ° C until metabolomic 
assessment. Th e samples were never thawed between storage and 
metabolomic analysis. Metabolic syndrome was diagnosed by the 
National Cholesterol Education Program’s Adult Treatment Panel 
III (NCEP/ATP III-a) criteria and smoking was defi ned as currently 
smoking one or more cigarettes per day. 17 Dietary data was collected 
using three separate, standardized 24-hour dietary recalls through 
the University of Michigan Dietetics Core. 18 Th e protocol was 
approved by the University of Michigan Medical Internal Review 
Board and was in accordance with the Decoration of Helsinki. 
 Untargeted metabolomics assessment 
 Serum samples were submitted for an untargeted metabolomics 
analysis through the NIH-supported Michigan Regional 
Comprehensive Metabolomics Resource Core (MRC 2 ). The 
core’s untargeted methodology has been previously published. 19 
Briefl y, Carbon-13 stable isotope internal standards, metabolite 
standards and all other reagents for the untargeted metabolomics 
assay were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Serum was extracted according to the methods of Bruce 
et al. utilizing a 1:1:1 methanol:acetonitrile:acetone extraction 
process. 20 A modifi ed version of the mixed-mode Hydrophobic 
Interaction Liquid Chromatography from Bajad et al. was used 
for separation on a Phenomenex (Torrence, CA, USA) Luna NH 2 
column where mobile Phase A was acetonitrile and mobile phase 
B was 5-mM ammonium acetate in water adjusted to pH 9.9 with 
ammonium hydroxide. 21 Th e supernatant from the extraction, 
also containing a mixture of the Carbon-13 internal standards, 
was added directly to autosampler vials for separation followed by 
analysis on an Agilent 1200 LC/6520 Time of Flight MS system. 
Mass spectrometry was performed in both negative and positive 
ion mode with electrospray ionization. 
 Aiglent Masshunter Qualitative Analysis soft ware (version 
4.0) was used for untargeted metabolite profi ling. Features were 
putatively identifi ed with relative quantifi cation using an in-house 
library that has been developed under the same LC-MS conditions 
and using the Metlin and the Human Metabolome Databases 
based on the  m / z values with an accuracy of 20 ppm. Th e core 
visually inspected the peak shapes of all features and discarded any 
artifacts. Features unable to be identifi ed via these methods were 
considered “unknowns” which were removed before statistical 
analysis. Th e core then exported the data to MZmine and returned 
a single preprocessed peak intensity table for both the positive and 
negative ion modes for downstream analysis by the investigators. 
 Statistical analyses 
 Demographic and clinical data are expressed as mean ± SD. 
Group comparison and statistical signifi cance was determined 
between (1) the antipsychotic and lithium bipolar-treated groups 
or (2) the antipsychotic-treated groups using unpaired, two-tailed 
Student’s  t -test or chi-square test depending on the variable using 
R statistical soft ware. A  p value of 0.05 or below was considered 
signifi cant for demographic analysis. 
 Th e peak intensity table containing the features identifi ed 
from the untargeted analysis were analyzed using the freely 
available online metabolomics processing soft ware Metaboanalyst 
3.0. 22 Unknowns and features that had >70% missing data in the 
samples were removed from downstream analysis and remaining 
missing data was addressed by replacing with half of the minimum 
positive value in the data set. 23 In order to assist in removing noise 
and noninformative values, low-quality data was then fi ltered using 
the robust interquantile ranges (IQR) method. 24 Normalization 
of data was performed by internal controls, autoscaling, and log 
transformation. Multivariate analyses were conducted using the 
partial least discriminant analysis (PLS-DA) to visually inspect 
metabolite profi le diff erences between the groups of interest. Th e 
PLS-DA model was validated by 100 random permutations of the 
Y variable and comparison of the goodness to fi t (R2Y and Q2) 
to the original model in the validation plot. 25 Two-dimensional 
score plots were produced to visually assess separation between 
groups. Variable importance in the projection (VIP) scores were 
used to identify the most infl uential features in the PLS-DA 
model. In determining the most infl uential features multiple 
testing correction was made using the Metaboanalyst default of 
False Discovery Rate (FDR) method. Finally, the Metaboanalyst 
pathway module was used to further investigate the top infl uential 
features of the PLS-DA model. 
 Results 
 Group analysis 
 Serum samples from a total of 62 bipolar I subjects were included 
for untargeted analysis. Th e average age of the bipolar groups was 
45.1 ± 11.5, 63% were female and 86% were Caucasian. Twenty 
schizophrenia patients treated with SGAs were chosen based on 
medication, age, race, and body mass index (BMI) to compare to 
434 VOLUME 8 • ISSUE 5 WWW.CTSJOURNAL.COM
Burghardt et al. ■ Untargeted Metabolomics in Bipolar Disorder
bipolar subjects on SGAs. Th e schizophrenia cohort had an average 
age of 45.9 ± 9.8, 50% were female and 90% were Caucasian. 
 In comparing the bipolar subjects on SGAs to those on 
lithium a signifi cant diff erence was identifi ed for the diagnosis of 
metabolic syndrome. Metabolic syndrome was more common for 
bipolar subjects on SGAs compared to the lithium-treated subjects 
(45.0 vs. 25.0, respectively,  p = 0.0470). Bipolar subjects on SGAs 
also had a signifi cantly lower ratio of dietary polyunsaturated fatty 
acids to saturated fatty acids (PUFA/SFA) compared to bipolar 
subjects on lithium, indicating an overall lower intake of PUFAs 
in the SGA-treated group. Additionally, systolic blood pressure 
was signifi cantly higher in the bipolar patients taking SGAs as 
compared to those on lithium ( p = 0.05), and diff erences in race/
ethnicity between these two groups approached signifi cance as 
well ( p = 0.07). Th e metabolic-related diff erences were expected 
given the known metabolic adverse eff ects of SGAs compared 
to lithium. 
 For demographic and clinical comparisons of the 
antipsychotic-treated bipolar and schizophrenia subjects, a 
signifi cantly higher amount of schizophrenia subjects smoked 
( p = 0.0383). Diastolic blood pressure ( p = 0.07) and HbA1C% 
( p = 0.08) approached, but did not reach, statistical signifi cance. 
Of note, gender did not signifi cantly diff er between the two 
antipsychotic groups ( p = 0.30). A full description of each group’s 
demographic, clinical and medication characteristics can be found 
in  Tables  1 and  2 . 
Treatment group Bipolar I on SGAs Bipolar I on lithium Schizophrenia on SGAs 
Sample size ( n ) 30 32 20 
Age 45.4 ± 11.9 44.1 ± 12.2 45.9 ± 9.8 
Gender (% female) 63.2 62.5 50.0 
% Caucasian 87.7 84.4 90.0 
% Currently smoking † 28.6 28.1 55.0 
Body mass index (kg/m 2 ; mean ± SD) 31.4 ± 8.5 32.2 ± 8.2 32.0 ± 6.83 
Waist to hip ration (WHR; mean ± SD) 1.08 ± 0.10 1.10 ± 0.11 1.06 ± 0.08 
Systolic blood pressure (mmHg; mean ± SD) * 125 ± 19.2 120 ± 13.0 118 ± 11.7 
Diastolic blood pressure (mmHg; mean ± SD) 75.8 ± 11.7 70.7 ± 10.6 70.5 ± 8.35 
Total cholesterol (mg/dL; mean ± SD) 196 ± 45.3 180 ± 37.5 177 ± 49.5 
Triglycerides (mg/dL; mean ± SD) 154 ± 115 123 ± 72.0 167 ± 123 
High-density lipoprotein (mg/dL; mean ± SD) 58.7 ± 18.2 55.5 ± 9.17 52.4 ± 15.3 
Low-density lipoprotein (mg/dL; mean ± SD) 120 ± 37.5 110 ± 33.8 105 ± 33.3 
HbA1C (%) 5.62 ± 0.64 5.79 ± 6.29 6.01 ± 1.14 
Glucose (mg/dL; mean ± SD) 98.2 ± 15.0 99.5 ± 29.3 105 ± 17.6 
% Metabolic syndrome * 46.0 25.0 55.0 
Dietary caloric intake (kcal; mean ± SD) 1,833 ± 555 2,008 ± 605 1,853 ± 337 
Dietary total fat intake (g; mean ± SD) 74.6 ± 31.0 76.6 ± 41.4 76.7 ± 16.4 
Dietary total carbohydrate intake (g; mean ± SD) 220 ± 91.5 226 ± 108 218 ± 79.9 
Dietary polyunsaturated to saturated fatty acid intake 
(mean ± SD) * 
0.703 ± 0.070 1.06 ± 0.110 0.666 ± 0.202 
Antidepressant use % 59 62 55 
 *Indicates statistically signifi cant difference between bipolar I on SGA and bipolar I on lithium based on an indepedent  t -test or a chi-square test. 
 †Indicates statistically signifi cant difference between bipolar I on SGA and schizophrenia on SGA based on an indepedent  t -test or a chi-square test. 
 Table 1.  Demographic and clinical characteristics of the three study groups. Values expressed as ±SD or %. 
Antipsychotic Bipolar I on SGAs Schizophrenia on SGAs 
 % on given antipsychotic Average dose (mg) % on given antipsychotic Average dose (mg) 
Olanzapine 16.7 12 20 16.7 
Clozapine 16.7 150 20 300 
Quetiapine 33 405 20 400 
Risperidone 20 3 20 5 
Aripiprazole 6.6 15 10 22 
Ziprasidone 6.6 120 10 140 
 Table 2.  Breakdown of antipsychotic frequency and dose for bipolar I subjects and schizophrenia subjects on second generation antipsychotics. No signifi cant differences 
existed between the groups when comparing antipsychotic use. 
435VOLUME 8 • ISSUE 5WWW.CTSJOURNAL.COM
Burghardt et al. ■ Untargeted Metabolomics in Bipolar Disorder
 Metabolome changes 
 Following preprocessing, 354 named features remained for 
analysis in negative mode and 480 named features were available 
for analysis from positive mode. PLS-DA modeling revealed 
divergent eff ects of current medication treatment and diagnosis 
on the serum metabolome ( Figure  1 ). Each model was validated 
by random permutation of each group. Permutation tests showed 
that each model was outside the distribution of random class 
assignments based on each respective between-group sum of the 
squares and within-group sum of squares (B/W) ratio (all  p < 
0.05). Goodness of Fit analysis for score plots between bipolar 
subjects resulted in a R2Y = 0.88 and Q2 = 0.79 for positive mode 
and a R2Y = 0.83 and Q2 = 0.55 for negative mode. Goodness of 
Fit analyses for score plots between bipolar and schizophrenia 
subjects results in a R2Y = 0.95 and Q2 = 0.52 for positive mode 
and a R2Y = 0.76 and Q2 = 0.44 for negative mode. 
 Variable importance in projection (VIP) scores were 
computed in order to investigate the metabolite features that 
were most responsible for the observed diff erences in each of the 
PLS-DA score plots. Th e top fi ve infl uential metabolites (with 
VIP > 1) listed as annotated features for each PLS-DA plot can 
be found in  Table  3 . 
 Figure 1.  Partial least squares discriminant analysis (PLS-DA) of untargeted metabolomics data from bipolar and schizophrenia subjects treated with antipsychotics or lithium. 
The two-dimensional PLS-DA score plots reveal separation between bipolar subjects treated with SGAs (red dots) compared to bipolar subjects treated with lithium (green 
dots) in both (a) negative and (b) positive ion mode. Additionally, plots show separation between bipolar subjects treated with SGAs (red dots) and schizophrenia subjects 
treated with SGAs (blue dots) in both (c) negative and (d) positive ion mode. Colored shaded areas correspond to each group's. 
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 Discussion 
 Discrimination of bipolar SGA use, bipolar lithium use, and 
schizophrenia SGA use 
 Bipolar disorder and schizophrenia pharmacotherapy can be 
diffi  cult to study given the psychotropic polypharmacy seen 
within both populations. 26,27 We attempted to overcome this 
limitation by limiting metabolomics analysis to patients stable 
on a restricted set of psychopharmacotherapy. Specifically, 
bipolar subjects were maintained on either lithium or SGA mood 
stabilization monotherapy while schizophrenia subjects were 
maintained on SGA monotherapy. Th e only other psychotropic 
agent that was common amongst each group was antidepressant 
therapy, which was well matched between the groups ( Table  1 ). 
PLS-DA score plots showed satisfactory visual separation and the 
models performed to varying degrees (see results) however all 
models achieved Q2 values >0.4 which has been considered as 
acceptable for certain human metabolomics studies. 28 
 In this study, the comparison of metabolite features between 
bipolar subjects on diff ering psychiatric pharmacotherapy as 
well as comparisons to a group of schizophrenia subjects treated 
with SGAs did show diff ering profi les. Th is may suggest that the 
pharmacometabolome may have within diagnosis and between 
diagnosis eff ects. Th e implications of such preliminary fi ndings and 
the hypotheses one can derive from them require further work and 
validation using specifi c targeted metabolomic approaches in pre- 
and postantipsychotic-treated populations in order to fully assess 
any diagnosis-specifi c eff ects on the pharmacometabolome. Several 
such studies have been completed in the schizophrenia population, 
but comparable data is lacking in the bipolar population. 
 Metabolite features characterizing distinction between 
antipsychotic- and lithium-treated bipolar subjects 
 Features that characterized the observed diff erences in the PLS-
DA score plot of bipolar subjects treated with SGAs and bipolar 
subjects treated with lithium came from several diff erent classes. 
Both the positive and negative ion modes identifi ed metabolite 
features from lipid and hydroxy acid classes. Pathway analysis 
of the top metabolite features from both modes revealed several 
pathways of interest, including those involved in the metabolism 
of linoleic acid, pyruvate, and glucose. It is reasonable to expect 
that variation in each of these metabolic pathways would be 
signifi cantly aff ected by antipsychotic use. 
 Pyruvate, a byproduct of glucose use in the TCA Cycle, 
is important in energy metabolism. Pyruvate metabolism has 
been investigated in the etiology of obesity, insulin resistance, 
and diabetes. 29 The effect of pyruvate administration and 
metabolism has also been investigated in SGA-induced metabolic 
disturbances. 30 Smith et al. found that pyruvate challenges in rats 
treated with olanzapine increased hepatic glucose output. Th is 
work suggested that the insulin resistance caused by SGAs may be 
due to indirect eff ects of antipsychotics to increase glucose output 
rather than directly inducing insulin resistance. Work has also 
shown that olanzapine administration increases gluconeogenesis 
by upregulation of several genes in the frontal cortex, including 
pyruvate kinase, the enzyme responsible for the production of a 
pyruvate from phosphoenolpyruvate. 31 
 Lactate, a product of pyruvate metabolism, was found to 
infl uence the metabolomic feature of risperidone response in 
the metabolomics study by Xuan et al. 13 Th eir work showed an 
increase in lactate in both responders and nonresponders to 
risperidone, which may indicate a drug eff ect not necessarily 
related to effi  cacy. Within the current study, L-Lactic Acid, 
was higher in bipolar subjects treated with lithium compared 
to bipolar subjects treated with SGAs. Although contradictory 
to the fi ndings of Xuan et al., other fi ndings have suggested an 
increase in gray matter lactate of bipolar subjects treated with 
lithium which may be related to our peripheral fi nding. 32 Without 
a healthy control comparator or longitudinal design, we cannot 
draw fi rm conclusions from the results of this analysis and fully 
compare to our lactate result to that of Xuan et al. However, this 
fi nding, in addition to previous work, may indicate that lactic 
acid and pyruvate metabolism are important pathways for further 
study in the bipolar and SGA-treated populations. 
 In addition to pyruvate being a top metabolite feature, the 
fi nding of metabolite features that infl uence glucose metabolism 
is to be expected as it has been a known eff ect of SGAs for many 
years. Finally, work has shown linoleic acid, which will be further 
described below, was infl uenced by SGA treatment, particularly 
in bipolar disorder. 
 Metabolite features characterizing distinction between SGA-
treated bipolar subjects and SGA-treated schizophrenia 
subjects 
 Comparisons of untargeted metabolite feature profi les between 
the bipolar and schizophrenia subjects treated with SGAs showed 
separation upon PLS-DA analysis. Infl uential metabolite features 
were associated with linoleic acid metabolism, biotin metabolism, 
valine, leucine, and isoleucine metabolism and degradation, and, 
glycerophospholipid metabolism. 
 Biotin is an important water-soluble B vitamin (B 7 ) used in two 
reactions involving amino acids: (1) leucine catabolism and (2) the 
use of methionine and threonine for the downstream production 
of succinyl CoA as it enters the TCA cycle. 33 Biotin also serves 
as the cofactor for the pyruvate and acetyl-CoA carboxylases in 
gluconeogenesis and fatty acid synthesis pathways. 34 Th e relative 
abundance of pimeleic acid, a precursor to biotin, was higher in 
the bipolar group compared to the schizophrenia group. Although 
pimelic acid has not been extensively studied in human disease, 
the supplementation and metabolism of biotin has been evaluated 
for therapeutic effi  cacy in improving metabolic control in diabetic 
patients. 35 It is not fully understood what role biotin metabolism 
may play in the SGA pharmacometabolome. Additional analyses 
of this pathway in SGA-induced insulin resistance may be 
warranted to further understand its importance, if any. 
 Another infl uential metabolite feature from our metabolomics 
comparison of a bipolar and a schizophrenia SGA-treated group 
was that of leucine. Leucine is one of several branched-chain 
amino acids (BCAA) known to serve as a precursor in the brain 
for the production of glutamate, which is essential for neuronal 
function in the brain. 36 In addition to this important function 
in the brain, the BCAAs have been implicated in both obesity 
and diabetes models 37 which may be of signifi cance given SGAs 
metabolic side eff ects. A recent metabolomics investigation by 
Wang et al. found that six branched-chain amino acids, including 
leucine, were predictive of the development of diabetes. 38 Within 
our study L-leucine was higher in schizophrenia subjects on SGAs. 
Previously, elevated leucine levels were identifi ed in the cerebral 
spinal fl uid of schizophrenia subjects, but these fi ndings were not 
replicated in the periphery of schizophrenia subjects treated with 
the SGA clozapine. 39 Amino acid supplementation has also been 
investigated in bipolar disorder and shown to improve manic 
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symptoms acutely. 40 Taken together, BCAA metabolism may be 
a feasible pathway for further study in both SGA effi  cacy and 
side eff ects. We believe this may be highlighted in the coming 
years with the advent of microbiome research within psychiatry. 
 Finally, another important pathway identified from our 
metabolomic comparisons of bipolar and schizophrenia subjects 
treated with SGAs was that of glycerophospholipids. Th ese are 
important components of cell membranes (including neural 
membranes) and include plasmalogens, phosphatidates, and 
phosphatidylcholines. Various phospholipid species have long 
been thought to be dysregulated in schizophrenia however, 
investigation of the associated pathways in bipolar disorder is 
lacking. Work has shown that antipsychotics interact with lipids 
to cause cell membrane reorganization and they can have diff erent 
affi  nities for particular lipid species, including phosphatidylcholine 
and plasmalogens. 41 Th is may suggest that antipsychotics are 
able to modulate receptor activity in the brain by altering the 
environment of the cell membrane. Our fi ndings here may further 
validate the lipidomic work by Kaddurha-Doak and McEvoy in 
which they have identifi ed, in two separate lipidomic studies, SGA-
induced changes in phospholipid and plasmalogen metabolism 
in schizophrenia subjects at various states (e.g., fi rst episode, 
recurrent) compared to healthy controls. 11,12 The particular 
lysophosphotidycholine identifi ed in our study had a higher 
relative abundance in SGA-treated bipolar subjects however, 
we did not have a healthy control comparator to identify if the 
levels of this metabolite were overall elevated. Nevertheless, this 
work adds to a continued theme in the literature of phospholipids 
playing an important role in antipsychotic outcomes. 
 Potential role of linoleic acid metabolism in antipsychotic 
treatment 
 A common pathway that emerged from the PLS-DA score plots 
of the three treatment groups in this study was that of the linoleic 
acid. Linoleic acid is an omega-6 polyunsaturated essential fatty 
acid (PUFA) that is used as a constituent of cell membranes and 
in the biosynthesis of arachidonic acid, which mediates neuronal 
transduction and can induce neurotransmission. 42 As an essential 
fatty acid that must be obtained from the diet, linoleic acid has 
been the subject of a large amount of cardiometabolic research. 
 The role of linoleic acid in human health and disease 
processes continues to be debated. It is generally thought that 
omega-6 PUFAs are correlated with proinfl ammatory mediator 
production while the parallel pathway of omega-3 PUFAs are anti-
infl ammatory. 43 PUFAs have been found to be infl uential in the 
few metabolomic and lipidomic studies involving antipsychotics 
to date. 
 In the schizophrenia lipidomic investigation by Kaddurah-
Daouk et al., they found that linoleic acid increases following 
antipsychotic treatment and determined that a deficiency 
of linoleic acid was not present in SGA-treated patients. 11 
Comparisons of the relative abundances of linoleic acid in our 
population showed similar results where bipolar subjects treated 
with SGAs had higher relative abundances of the metabolite 
compared to bipolar subjects treated with lithium. In the 
untargeted metabolomic study in schizophrenia by Xuan et al., 
they found increases in linoleic acid aft er risperidone treatment 
and particularly, in responders to risperidone. 13 They also 
showed that linoleic acid had a high statistical likelihood for both 
explaining metabolite profi le diff erences and being predictive of 
risperidone response. 
 Although work has consistently ruled out linoleic acid 
defi ciencies in antipsychotic-treated patients, there continues 
to be debate on the eff ect of antipsychotics on infl ammatory 
status in patients. 44–47 One possible reason for these seemingly 
confl icting fi ndings may be that linoleic acid plays diff erent roles 
within diagnostic populations that have distinct dietary and 
environmental conditions. Furthermore, it could be that increases 
in linoleic acid leads to an imbalance between omega-6 and 
omega-3 PUFAs (or between particular species in each pathway) 
further leading to altered cell membrane stability and downstream 
negative eff ects. It is not known what this correct “balance” 
may be, if there is indeed one. One study did identify diff ering 
ratios of proinfl ammatory to antiinfl ammatory mediators when 
comparing bipolar disorder patients to schizophrenia patients 48 
however they did not investigate PUFA profi les. Finally, other 
factors, including genetic polymorphisms of the Fatty Acid 
Desaturase (FAD) genes, which are responsible for PUFA 
metabolism, have been shown to play a role in antipsychotic 
outcomes. 49 
 A highly targeted approach to investigating PUFA metabolism 
may help to further clarify the interaction of infl ammation 
and SGAs and whether it plays a role in both bipolar disorder 
and schizophrenia or rather a particular population. Pre and 
postmeasures in antipsychotic-treated populations are needed 
and should include metabolite and inflammatory levels, 
genotyping and gene expression and possibly epigenetic work. 
Indeed, work on this pathway has already started within bipolar 
disorder disease risk with signifi cant outcomes. 50 Evans et al. 
demonstrated linoleic acid disturbances in bipolar subjects 
compared to healthy controls, which may be partly attributable 
to dietary and psychiatric medication use. Th us it can be seen that 
that this pathway may have a pivotal role in both bipolar disorder 
disease burden as well as SGA outcomes. 
 Limitations 
 Th e major limitation of the current study is its cross-sectional 
design and lack of healthy control group that limits our ability to 
draw causal conclusions from the relationships identifi ed between 
SGA use and diagnosis. As mentioned, prospective studies 
assessing metabolome changes before and aft er SGA treatment 
in bipolar disorder is needed. Furthermore, although the use of 
an untargeted metabolomic platform enables us to better assess 
the global pharmacometabolome of the subject populations in 
this work, targeted and quantitative work must follow to fully 
assess the usefulness of the identifi ed pathways as biomarkers 
for treatment outcome. 
 Conclusions 
 Th e purpose of this work was to describe the outcomes of an 
untargeted metabolomic analysis of SGA use in bipolar disorder 
by conducting a within diagnosis comparison and across diagnosis 
comparison. Th e analyses presented in this study are essential to 
enable scientists, and ultimately clinicians, to better understand 
the input of disease-specifi c processes on the metabolome versus 
the eff ects environmental eff ects such as medications, diet and 
lifestyle. Distinct metabolite features were identifi ed between 
SGA-treated bipolar subjects, lithium-treated bipolar subjects 
and SGA-treated schizophrenia subjects. Pathways of interest 
were identifi ed for further study including biotin, pyruvate, and 
linoleic acid metabolism. Many of these fi ndings support other 
pharmacometabolomic work conducted in the schizophrenia 
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population treated with antipsychotics. Th is study’s fi ndings add 
to a growing body of literature showing PUFAs like linoleic acid 
may play an important role in both disease specifi c processes and 
SGA outcomes in bipolar disorder. 
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